January 8, 2019
Otsuka Pharmaceutical Co., Ltd.
H. Lundbeck A/S
Selincro (nalmefene) Tablets 10mg Receives Regulatory Approval in Japan
First Drug Approved in Japan to Reduce Alcohol Consumption in Alcohol-dependent Patients
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A / S of Denmark are pleased to announce that Otsuka has received regulatory approval in Japan for the manufacture and sale of Selincro Tablets 10 mg (generic name: nalmefene hydrochloride), a therapeutic drug treatment to reduce alcohol consumption in alcohol-dependent patients.
In 2013 Otsuka formed an agreement with Lundbeck on the development and commercialization in Japan of Lundbeck's nalmefene.
Information in this news release was current as of the original release date.